Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-08-01 00:00:00 ET · period of report 2022-07-28 · accession 0000899243-22-027173 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-08-01 | 2022-07-28 | KLRS | Hallal David | Dir, 10% | A - Grant | $4.61 | +3.25M | 16.67M | +24% | +$15.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-28 | A | A | 3,253,796 | $4.61 | 16,674,766 | I By ElevateBio LLC | — | — | (F2) Shares held by ElevateBio. The Reporting Person is the Chairman and Chief Executive Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |